Australia is pretty much middle of the pack when it comes to biotech R&D for a wider context for interest in PAR's science:
A decent report on the wider context:
https://mckellinstitute.org.au/wp-content/uploads/2022/02/McKell_BioSavvy_FINAL.pdf
Meanwhile, perhaps individually regerds the company, more investors should be asking direct questions of PR at AGM's, EGM's and the like. The delivery of timelines and alluded to progress has rarely met suggested timeframes and guidance.
It's bio-tech, management always over-promise and under deliver. But would suggest some of these fall a good way short of previous guidance.
On a more positive note, some progress in this report in keeping with recently described forthcoming deliveries at least (AGM guidance):
Qtlry:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-201
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |